{"id":15966,"date":"2024-12-01T11:12:11","date_gmt":"2024-12-01T03:12:11","guid":{"rendered":"https:\/\/flcube.com\/?p=15966"},"modified":"2024-12-01T11:12:14","modified_gmt":"2024-12-01T03:12:14","slug":"shanghai-cell-therapy-groups-second-attempt-at-hk-ipo-receives-green-light-from-cicc-and-ccb-international","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15966","title":{"rendered":"Shanghai Cell Therapy Group&#8217;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International"},"content":{"rendered":"\n<p>Shanghai Cell Therapy Group Co., Ltd., a leading player in China&#8217;s cellular medical health sector, has announced its second filing for an IPO on the Hong Kong Stock Exchange (HKEX), with joint sponsors being China International Capital Corporation Hong Kong Securities Limited (CICC) and CCB International Financial Limited (CCB International) .<\/p>\n\n\n\n<p><strong>Company Overview and Business Scope<\/strong><br>Established in 2013, Shanghai Cell Therapy Group is recognized as the first and only company in China that covers the entire value chain of cellular medical health. The company&#8217;s business scope spans across cell storage, oncology services, cellular pharmaceuticals, and cell energizing solutions. Supported by proprietary underlying technology platforms such as nanoantibody cell navigation and control, non-viral gene writing, and nucleic acid synthesis and delivery, Shanghai Cell Therapy Group is poised to leverage its comprehensive capabilities in the cellular therapy space .<\/p>\n\n\n\n<p><strong>Business Segment Maturity and Market Performance<\/strong><br>The company&#8217;s four main business segments show varying levels of maturity. In the cell storage business, which is the company&#8217;s main revenue stream, Shanghai Cell Therapy Group ranks first in China&#8217;s immune cell storage market in terms of both incremental and cumulative storage volumes for the years 2021-2023, according to data from China Insights Consultancy (CIC). In oncology medical services, the utilization rate of open beds at the company&#8217;s affiliated Mengchao Cancer Hospital, Shanghai University, increased from 40.3% in 2021 to 56.8% in the first half of 2024. However, in the cellular pharmaceutical R&amp;D field, all products are still in early clinical or pre-clinical development stages, and cell energizing products only began sales in the second half of 2023.<\/p>\n\n\n\n<p><strong>Financial Performance and Growth<\/strong><br>Shanghai Cell Therapy Group has achieved continuous revenue growth, increasing from RMB 498.5 million in 2021 to RMB 759.9 million in 2023, with a compound annual growth rate of 23.5%. In the first half of 2024, revenue reached RMB 434.1 million, a year-on-year increase of 24.2%. Despite significant R&amp;D investments and infrastructure construction leading to continuous losses during the performance record period\u2014with net losses of RMB 465.7 million, RMB 541.5 million, and RMB 488.1 million in 2021, 2022, and 2023 respectively, and a narrowed net loss of RMB 194.7 million in the first half of 2024\u2014the company&#8217;s financial trajectory indicates a commitment to growth and development in the cellular therapy sector.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Cell Therapy Group Co., Ltd., a leading player in China&#8217;s cellular medical health sector,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":15968,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[72,2511],"class_list":["post-15966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-ipo","tag-shanghai-cell-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Cell Therapy Group&#039;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Cell Therapy Group Co., Ltd., a leading player in China&#039;s cellular medical health sector, has announced its second filing for an IPO on the Hong Kong Stock Exchange (HKEX), with joint sponsors being China International Capital Corporation Hong Kong Securities Limited (CICC) and CCB International Financial Limited (CCB International) .\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15966\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Cell Therapy Group&#039;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15966\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-01T03:12:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-01T03:12:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Cell Therapy Group&#8217;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International\",\"datePublished\":\"2024-12-01T03:12:11+00:00\",\"dateModified\":\"2024-12-01T03:12:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0199.png\",\"keywords\":[\"IPO\",\"Shanghai Cell Therapy\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15966#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15966\",\"name\":\"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0199.png\",\"datePublished\":\"2024-12-01T03:12:11+00:00\",\"dateModified\":\"2024-12-01T03:12:14+00:00\",\"description\":\"Shanghai Cell Therapy Group Co., Ltd., a leading player in China's cellular medical health sector, has announced its second filing for an IPO on the Hong Kong Stock Exchange (HKEX), with joint sponsors being China International Capital Corporation Hong Kong Securities Limited (CICC) and CCB International Financial Limited (CCB International) .\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15966\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0199.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0199.png\",\"width\":1080,\"height\":720,\"caption\":\"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15966#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Cell Therapy Group&#8217;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Cell Therapy Group Co., Ltd., a leading player in China's cellular medical health sector, has announced its second filing for an IPO on the Hong Kong Stock Exchange (HKEX), with joint sponsors being China International Capital Corporation Hong Kong Securities Limited (CICC) and CCB International Financial Limited (CCB International) .","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15966","og_locale":"en_US","og_type":"article","og_title":"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15966","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-01T03:12:11+00:00","article_modified_time":"2024-12-01T03:12:14+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15966#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15966"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Cell Therapy Group&#8217;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International","datePublished":"2024-12-01T03:12:11+00:00","dateModified":"2024-12-01T03:12:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15966"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=15966#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","keywords":["IPO","Shanghai Cell Therapy"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15966#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15966","url":"https:\/\/flcube.com\/?p=15966","name":"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=15966#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=15966#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","datePublished":"2024-12-01T03:12:11+00:00","dateModified":"2024-12-01T03:12:14+00:00","description":"Shanghai Cell Therapy Group Co., Ltd., a leading player in China's cellular medical health sector, has announced its second filing for an IPO on the Hong Kong Stock Exchange (HKEX), with joint sponsors being China International Capital Corporation Hong Kong Securities Limited (CICC) and CCB International Financial Limited (CCB International) .","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15966#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15966"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=15966#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","width":1080,"height":720,"caption":"Shanghai Cell Therapy Group's Second Attempt at HK IPO Receives Green Light from CICC and CCB International"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15966#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Cell Therapy Group&#8217;s Second Attempt at HK IPO Receives Green Light from CICC and CCB International"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0199.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15966"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15966\/revisions"}],"predecessor-version":[{"id":15969,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15966\/revisions\/15969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/15968"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}